Compare RNXT & VIVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNXT | VIVO |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Power Generation |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.0M | 37.5M |
| IPO Year | 2021 | N/A |
| Metric | RNXT | VIVO |
|---|---|---|
| Price | $0.82 | $4.47 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.25 | N/A |
| AVG Volume (30 Days) | 263.2K | ★ 1.4M |
| Earning Date | 05-14-2026 | 05-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,123,000.00 | N/A |
| Revenue This Year | $194.66 | N/A |
| Revenue Next Year | $279.78 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2511.63 | N/A |
| 52 Week Low | $0.70 | $1.97 |
| 52 Week High | $1.45 | $5.25 |
| Indicator | RNXT | VIVO |
|---|---|---|
| Relative Strength Index (RSI) | 37.44 | 66.82 |
| Support Level | $0.81 | $2.87 |
| Resistance Level | $1.07 | N/A |
| Average True Range (ATR) | 0.05 | 0.47 |
| MACD | -0.00 | 0.14 |
| Stochastic Oscillator | 11.42 | 69.16 |
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.